In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aspen takes an option to acquire 11 drugs from Merck for $600mm

Executive Summary

South African pharmaceuticals company Aspen Pharmacare Holdings Ltd. is continuing on a 14-month long spending spree by taking an option to acquire 11 branded finished dosage form molecules from Merck Sharp & Dohme Ltd., the ex-US division of Merck & Co. Inc. The companies expect that Aspen will exercise the options by the end of 2013, at which point it would pay Merck $600mm.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • Reverse Licensing

Related Companies